Navigation Links
CryoLife Receives Expanded Indication for BioFoam in Europe
Date:12/5/2012

ATLANTA, Dec. 5, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it has received regulatory approval in Europe to market its BioFoam® Surgical Matrix as an adjunct to hemostasis in cardiovascular surgery when cessation of bleeding by ligature or other conventional methods is ineffective or impractical.  BioFoam has previously been approved in Europe as an adjunct to hemostasis in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical.

"We are pleased to receive an expanded indication for BioFoam in Europe," said Steven G. Anderson, CryoLife president and chief executive officer. "We have been encouraged by the early clinical experience in Europe with liver and spleen procedures and believe the product is well suited to provide rapid hemostasis in cardiovascular surgeries.  This expanded indication aligns with our BioGlue and PerClot market opportunity in Europe, giving us another sales driver and product to add to our selling efforts for our core cardiovascular surgeon customers.  BioFoam is an important extension to our portfolio, providing a solution for cardiac surgical needs, as a combination sealant/hemostat."

CryoLife estimates the annual European market opportunity for BioFoam, including for cardiovascular and parenchymal tissues, BioGlue and PerClot is more than $100 million[1].

[1] Based on Millennium Research Group (European Markets for Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers 2012; and European Surgical Procedure Volumes 2010) and Company estimates.

About BioFoam

BioFoam, a protein hydrogel biomaterial developed by CryoLife, contains an expansi
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
2. CryoLife Completes Acquisition of Hemosphere
3. CryoLife to Participate in 3rd Annual Benchmark Company, LLC One-on-One Investor Conference
4. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
5. CryoLife Reports 13% Revenue Growth for Second Quarter 2012
6. CryoLife Announces Initiation of Quarterly Cash Dividend
7. CryoLife Reports 13% Revenue Growth for Third Quarter 2012
8. CryoLife to Participate in Lazard Capital Markets 9th Annual Healthcare Conference
9. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
10. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
11. Nephros Receives 510(k) Clearance for Hemodiafiltration System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- CAS Medical Systems, Inc. (NASDAQ: CASM ) (CASMED), ... announced that Thomas M. Patton , President ... Annual Marcum MicroCap Conference on Thursday, May 30, 2013, ... City . The presentation is scheduled to ... and will be available via a live webcast at ...
(Date:5/23/2013)...  Omeros Corporation (NASDAQ: OMER ) ... (IND) to evaluate OMS824 in Huntington,s disease has ... Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), ... linked to a wide range of diseases that ... has shown promising results in animal models directly ...
(Date:5/23/2013)... , May 23, 2013  Echo Pharma Acquisition Limited ... waive down the Acceptance Threshold from 90 percent to ... Elan Share in accordance with the terms of the ... summarized below. Under the terms of the ... (NYSE: ELN ) for $12.50 per share ...
Breaking Medicine Technology:CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10
(Date:5/23/2013)... 23 (HealthDay News) -- A shortage of a critical ... across the United States to contain the spread of ... The drug, isoniazid (INH), was first used in 1951 ... the core of any first-line treatment for tuberculosis (TB). ... months, according to the U.S. Centers for Disease Control ...
(Date:5/23/2013)... have shown that an immune regulatory molecule called IL-21 ... viral infections. , The results are published in the ... how IL-21 could be important in the development of ... PhD, the first author of the paper. The senior ... Vaccine Center and a Georgia Research Alliance Eminent Scholar. ...
(Date:5/23/2013)... 2013 Netsmart today announced it ... of healthcare information technology (HIT) providers for 2013. , The ... of Healthcare Informatics magazine. Netsmart’s ranking of #49 ... strong continued growth is largely due to our commitment to ... of healthcare where resources are scarce, the demand for care ...
(Date:5/23/2013)... researchers examining outcomes for advanced heart-failure patients over ... with the increased availability and use of new ... death, caused by the rapid onset of severe ... However, the team found that even today, with ... more than three years after being diagnosed with ...
(Date:5/23/2013)... Elegance for a woman takes on so many ... her intrigue can often be found in the mystery of her ... soul is through her eyes. It is also true that ... is why the elegance of a woman can be found in ... more than any other time, utilize eyewear to not only compliment ...
Breaking Medicine News(10 mins):Health News:Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 2Health News:Vaccine blackjack: IL-21 critical to fight against viral infections 2Health News:Netsmart Named to Healthcare Informatics Top 100 List 2Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 2Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 3Health News:Dolabany Eyewear Adds Feminine Flare to Women's Designer Eyewear with 2013 New Release of Adelina by Best Image Optical, Inc. 2
... James S. Forrester, M.D., former chief of the ... the 2009 Lifetime Achievement Award from the American College ... March 29. , Currently the George Burns ... Forrester came to the medical center in 1969 as ...
... These new insights represent an important contribution to future ... prestigious science journal Nature and will be ... molecular mechanisms of hematopoiesis, which will take place in ... findings on the molecular mechanisms of blood formation (hematopoiesis) ...
... Overestimate Amount of Time it Takes to Form a New ... to Achieving Healthier HabitsGREENWICH, Conn., April 1 ... Nestle(R) Pure Life (R) brand bottled water, the number one ... think it takes six months or longer to form a ...
... PALM BEACH GARDENS, Fla., April 1 As ... http://www.silvercensus.com ), a national web ... announced today that it is urging American Veterans ... entitlement from the Veterans Administration called "Aid and ...
... Mass., April 1, EnVivo Pharmaceuticals today ... Corporation (MTPC) for the development and commercialization ... Japan and several other Asian countries. EVP-6124 ... agonist currently in development for cognition enhancement ...
... April 1 Immunotech Laboratories, Inc. Immunotech Laboratories ... in Puerto Rico with its abstract " Irreversible ... specific novel cytokine stimulation in vitro investigation of ... at the 5th European Conference on Clinical and ...
Cached Medicine News:Health News:ACC presents lifetime achievement award to Cedars-Sinai Heart Institute's James Forrester, M.D. 2Health News:Last step leading to blood cell formation elucidated 2Health News:Video: New Survey Reveals Misconceptions About Forming New Habits 2Health News:Video: New Survey Reveals Misconceptions About Forming New Habits 3Health News:Video: New Survey Reveals Misconceptions About Forming New Habits 4Health News:Little-Known VA Care Entitlement for Veterans Highlighted by SilverCensus.com 2Health News:Little-Known VA Care Entitlement for Veterans Highlighted by SilverCensus.com 3Health News:EnVivo and Mitsubishi Tanabe Enter License Agreement on EVP-6124 in Japan, Korea, Taiwan and Other Asian Countries 2Health News:EnVivo and Mitsubishi Tanabe Enter License Agreement on EVP-6124 in Japan, Korea, Taiwan and Other Asian Countries 3Health News:Beating a Global Killer: HIV/AIDS 2Health News:Beating a Global Killer: HIV/AIDS 3Health News:Beating a Global Killer: HIV/AIDS 4
...
The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
Codman periosteal elevators, sharp, length 8" (203 mm), blade width 3/16" (5 mm)....
Hoen periosteal elevators, No.3, blade width 3/4" (20 mm), total length 7 1/2" (191 mm)....
Medicine Products: